{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:40:06Z","timestamp":1781019606582,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["HTA-10-46-01"],"award-info":[{"award-number":["HTA-10-46-01"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pilgrim Trust"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jsat.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:48:57Z","timestamp":1547639337000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study"],"prefix":"10.1016","volume":"99","author":[{"given":"Charlotte N.E.","family":"Tompkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Neale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-2725","authenticated-orcid":false,"given":"John","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jsat.2019.01.012_bb0005","doi-asserted-by":"crossref","DOI":"10.3310\/hta11060","article-title":"Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation","volume":"11","author":"Adi","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.jsat.2019.01.012_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13722-015-0034-5","article-title":"Factors associated with willingness to take extended release naltrexone among injection drug users","volume":"10","author":"Ahamad","year":"2015","journal-title":"Addiction Science & Clinical Practice"},{"issue":"3","key":"10.1016\/j.jsat.2019.01.012_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2045125316681984","article-title":"Probuphine\u00ae (buprenorphine implant): A promising candidate in opioid dependence","volume":"7","author":"Barnwal","year":"2017","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.jsat.2019.01.012_bb0020","series-title":"Developing and evaluating complex interventions: New guidance","author":"Craig","year":"2008"},{"issue":"3","key":"10.1016\/j.jsat.2019.01.012_bb0025","first-page":"41","article-title":"Why do heroin users refuse to participate in a heroin-assisted treatment trial?","volume":"16","author":"Demaret","year":"2014","journal-title":"Heroin Addiction and Related Clinical Problems"},{"issue":"2","key":"10.1016\/j.jsat.2019.01.012_bb0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2014.09.002","article-title":"Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community","volume":"39","author":"Di Paola","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"5","key":"10.1016\/j.jsat.2019.01.012_bb0035","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/0269216318757623","article-title":"Using the \u2018social marketing mix framework\u2019 to explore recruitment barriers and facilitators in palliative care randomised clinical trials? A narrative systematic review","volume":"32","author":"Dunleavy","year":"2018","journal-title":"Palliative Medicine"},{"key":"10.1016\/j.jsat.2019.01.012_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jsat.2017.11.008","article-title":"Effectiveness, implementation and real-world experience with extended-release naltrexone (XR-NTX): A special issue of JSAT","volume":"85","author":"Friedmann","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.01.012_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1745-6215-15-182","article-title":"Using marketing theory to inform strategies for recruitment: A recruitment optimisation model and the txt2stop experience","volume":"15","author":"Galli","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.jsat.2019.01.012_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-7517-6-2","article-title":"NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America","volume":"6","author":"Gartry","year":"2009","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2019.01.012_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2014.03.046","article-title":"Naltrexone: A review of existing sustained drug delivery systems and emerging nano-based systems","volume":"183","author":"Goonoo","year":"2014","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jsat.2019.01.012_bb0060","series-title":"National Guidelines for medication-assisted treatment of opioid dependence","author":"Gowing","year":"2014"},{"key":"10.1016\/j.jsat.2019.01.012_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000447964","article-title":"Interest in extended release naltrexone among opioid users","volume":"22","author":"Haase","year":"2016","journal-title":"European Addiction Research"},{"key":"10.1016\/j.jsat.2019.01.012_bb0070","author":"Health Technology Assessment Programme"},{"key":"10.1016\/j.jsat.2019.01.012_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0253-7176.112194","article-title":"Long-acting preparations in substance abuse management: A review and update","volume":"35","author":"Hegde","year":"2013","journal-title":"Indian Journal of Psychological Medicine"},{"issue":"10","key":"10.1016\/j.jsat.2019.01.012_bb0080","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone","volume":"66","author":"Hulse","year":"2009","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1016\/j.jsat.2019.01.012_bb0085","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.01.012_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2288-13-145","article-title":"Using a social marketing framework to evaluate recruitment of a prospective study of genetic counseling and testing for the deaf community","volume":"13","author":"Kobayashi","year":"2013","journal-title":"BMC Medical Research Methodology"},{"issue":"9","key":"10.1016\/j.jsat.2019.01.012_bb0095","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jsat.2019.01.012_bb0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","article-title":"Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available","volume":"12","author":"Krupitsky","year":"2010","journal-title":"Current Psychiatry Reports"},{"issue":"6","key":"10.1016\/j.jsat.2019.01.012_bb0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","article-title":"Naltrexone implants after inpatient treatment for opioid dependence: Randomised controlled trial","volume":"194","author":"Kun\u00f8e","year":"2009","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.01.012_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence","volume":"33","author":"Larney","year":"2014","journal-title":"Drug and Alcohol Review"},{"issue":"10118","key":"10.1016\/j.jsat.2019.01.012_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jsat.2019.01.012_bb0120","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2019.01.012_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000313336","article-title":"Naltrexone implants compared to methadone: Outcomes six months after prison release","volume":"16","author":"Lobmaier","year":"2010","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1016\/j.jsat.2019.01.012_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/16066350802531273","article-title":"Treatment research in prison: Problems and solutions in a randomized trial","volume":"18","author":"Lobmaier","year":"2010","journal-title":"Addiction Research and Theory"},{"issue":"2","key":"10.1016\/j.jsat.2019.01.012_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JAN.0000000000000223","article-title":"Sublocade the once-monthly buprenorphine injectable","volume":"29","author":"Lorman","year":"2018","journal-title":"Journal of Addictions Nursing"},{"key":"10.1016\/j.jsat.2019.01.012_bb0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jsat.2018.01.003","article-title":"A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine","volume":"86","author":"Marcus","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.01.012_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.07.010","article-title":"Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine","volume":"179","author":"Marcus","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.01.012_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1465-3362.2009.00096.x","article-title":"Ineligibility and refusal to participate in randomised trials of treatments for drug dependence","volume":"29","author":"Melberg","year":"2010","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2019.01.012_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1016\/j.jsat.2019.01.012_bb0160","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/add.13314","article-title":"Iterative categorization (IC): A systematic technique for analysing qualitative data","volume":"111","author":"Neale","year":"2016","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.jsat.2019.01.012_bb0165","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/add.14163","article-title":"Improving recruitment to pharmacological trials for illicit opioid use: Findings from a qualitative focus group study","volume":"113","author":"Neale","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.01.012_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.01.012_bb0175","author":"NICE"},{"key":"10.1016\/j.jsat.2019.01.012_bb0180","doi-asserted-by":"crossref","first-page":"157S","DOI":"10.1177\/0898264304269727","article-title":"Social marketing as a framework for recruitment: Illustrations from the REACH study","volume":"16","author":"Nichols","year":"2004","journal-title":"Journal of Aging and Health"},{"key":"10.1016\/j.jsat.2019.01.012_bb0185","series-title":"Big pocket guide to using social marketing for behaviour change","author":"NSMC","year":"2011"},{"key":"10.1016\/j.jsat.2019.01.012_bb0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.jsat.2019.01.012_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40814-015-0026-y","article-title":"Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: Guidance for researchers","volume":"1","author":"O'Cathain","year":"2015","journal-title":"Pilot and Feasibility Studies"},{"key":"10.1016\/j.jsat.2019.01.012_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1747-597X-10-3","article-title":"The SALOME study: Recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency","volume":"10","author":"Oviedo-Joekes","year":"2015","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2019.01.012_bb0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1740774509105222","article-title":"Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study","volume":"6","author":"Oviedo-Joekes","year":"2009","journal-title":"Clinical Trials"},{"key":"10.1016\/j.jsat.2019.01.012_bb0210","first-page":"115","article-title":"Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management","volume":"6","author":"Reece","year":"2012","journal-title":"Substance Abuse: Research and Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2019.01.012_bb0215","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.01.012_bb0220","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/add.13539","article-title":"Food and drug administration approval of sustained release buprenorphine for treatment of opioid dependence: Realizing its potential","volume":"112","author":"Sigmon","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.01.012_bb0225","series-title":"Doing qualitative research: A practical handbook","author":"Silverman","year":"2000"},{"issue":"2","key":"10.1016\/j.jsat.2019.01.012_bb0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1108\/09654280710731548","article-title":"A systematic review of social marketing effectiveness","volume":"107","author":"Stead","year":"2007","journal-title":"Health Education"},{"key":"10.1016\/j.jsat.2019.01.012_bb0235","unstructured":"Strang J., Kelleher M., Mayet S., Day E., Hellier J., Byford S., \u2026 Marsden J., (in press). Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: The NEAT three-arm RCT, Health Technology Assessment."},{"key":"10.1016\/j.jsat.2019.01.012_bb0240","series-title":"HHS publication no. (SMA) 18-5063FULLDOC","article-title":"Medications to treat opioid use disorder. Treatment improvement protocol (TIP) series 63, full document","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2018"},{"issue":"12","key":"10.1016\/j.jsat.2019.01.012_bb0245","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2019.01.012_bb0250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09595230701829561","article-title":"Issues with recruitment to randomised controlled trials in the drug and alcohol field: A literature review and Australian case study","volume":"27","author":"Thomson","year":"2008","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2019.01.012_bb0255","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of Polydrug dependence: A randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.01.012_bb0260","author":"Titan Pharmaceuticals"},{"key":"10.1016\/j.jsat.2019.01.012_bb0265","series-title":"World drug report 2018","author":"United Nations","year":"2018"},{"issue":"3","key":"10.1016\/j.jsat.2019.01.012_bb0270","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000092115","article-title":"Naltrexone implants: Duration, tolerability and clinical usefulness","volume":"12","author":"Waal","year":"2006","journal-title":"European Addiction Research"},{"issue":"9","key":"10.1016\/j.jsat.2019.01.012_bb0275","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"14","key":"10.1016\/j.jsat.2019.01.012_bb0280","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10826084.2016.1201117","article-title":"Acceptability of extended-release naltrexone by heroin-dependent patients and addiction treatment providers in the Netherlands","volume":"51","author":"Zaaijer","year":"2016","journal-title":"Substance Use & Misuse"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:31Z","timestamp":1760039371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218305026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":56,"alternative-id":["S0740547218305026"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.01.012","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}